Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies
Authors not listed
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2019
Abstract
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria).
The primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality.
Other secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and/or urgent care due to cardiovascular complications, hospitalization and/or urgent oncological care due to cancer complications, tumor progression and cost-effectiveness analysis.
A total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized anti-tumoral treatment, will be recruited.
The incidence of primary and secondary outcomes will be measured at 2 and 5 years
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Anonymous. (2019). Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies. <em>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</em>. https://clinicaltrials.gov/study/NCT03711110
Vancouver
Anonymous. Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies. Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León. 2019.
BibTeX
@misc{anon2019Cardio,
title = {Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies},
author = {Anonymous},
journal = {Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Valencia 2016
Open access · US-GOV
Randomized Comparison Between a Strategy of Intervention in Frailty Versus the Usual Care in Frail Patients After an Acute Myocardial Infarction
SCRI Development Innovations, LLC 2002
Open access · US-GOV
Phase II Trial of Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital 2026
Open access · US-GOV
Association of Time to Intensive Care Unit Admission, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients Admitted From the Emergency Department to the Anesthesiology and Reanimation Intensive Care Unit
Centro di Riferimento Oncologico - Aviano 2010
Open access · US-GOV
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib
Ankara Training and Research Hospital 2025
Open access · US-GOV
Investigation of the Relationship Between Nutritional Status Assessment and Frailty in Critical Care Patients
Van Training and Research Hospital 2026
Open access · US-GOV